NASDAQ · Biotechnology

ZYME (ZYME) Stock

$22.62 +2.77% NASDAQ: ZYME Healthcare

Valuation

MetricValue
Price$22.62
Market Cap$1.66B
P/E Ratio40.73
P/B Ratio6.64
P/S Ratio21.67
EPS (TTM)$-1.37
52-Week High$29.75
52-Week Low$10.93
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-42.02%
ROA-15.77%
ROCE-34.57%
Gross Margin-67.01%
Operating Margin-19.57%
Net Margin-1.26%
Debt/Equity0.10
Current Ratio10.82

Annual Financials (USD)

Metric20212022202320242025
Revenue$27.0M$412.0M$76.0M$76.0M$106.0M
Operating Profit$-216.0M$131.0M$-138.0M$-137.0M$-93.0M
Net Profit$-212.0M$124.0M$-119.0M$-123.0M$-81.0M
EPS$-4.61$1.90$-1.72$-1.62$-1.08
Op Margin-808.2%31.6%-181.6%-179.7%-87.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$389.0M$649.0M$581.0M$463.0M$347.0M
Total Liabilities$140.0M$156.0M$116.0M$124.0M$78.0M
Cash$202.0M$401.0M$158.0M$66.0M$41.0M
Borrowings$32.0M$28.0M$27.0M$19.0M$18.0M

Latest News

Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026 GlobeNewswire · Jul 16, 2026 Truist Remains Bullish on Zymeworks (ZYME) – Here’s Why Insider Monkey · Jul 15, 2026 Zymeworks (ZYME) Stock Looks Fully Valued Despite Its 205% Three Year Run Simply Wall St. · Jul 1, 2026 Is Zymeworks Inc. (ZYME) Stock an Undervalued Biotech Opportunity With Oncology Growth Ahead? Insider Monkey · Jun 30, 2026 Theravance Stock Down 3% After Zymeworks Announces Buyout Zacks · Jun 30, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-192.0M$144.0M$-118.0M$-110.0M$-33.0M
Investing Cash Flow$131.0M$-67.0M$-211.0M$36.0M$25.0M
Financing Cash Flow$8.0M$1.0M$6.0M$-20.0M$-42.0M
Net Cash Flow$-40.0M$199.0M$-243.0M$-91.0M$-25.0M
Free Cash Flow$-206.0M$131.0M$-122.0M$-113.0M$-35.0M

Valuation & Return Ratios

MetricValue
PEG Ratio120.22
EV / EBITDA-12.97
FCF Yield-2601.73%
Quick Ratio10.82
Interest Coverage—
Return 1Y63.12%
Return 3Y215.43%
Return 5Y-34.23%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $313.33 +0.29% 37.72 $4.60T 0.34%
MSFTMicrosoft Corporation $499.99 +0.03% 22.95 $3.71T 0.94%
GOOGLAlphabet Inc. $354.30 -0.96% 27.68 $4.29T 0.23%
AMZNAmazon.com, Inc. $274.48 +0.82% 28.76 $2.95T 0.00%
METAMeta Platforms, Inc. $592.10 +0.37% 21.47 $1.51T 0.35%

About ZYME

ZYME stock trades at $22.62 with a market capitalization of $1.66B. The stock is valued at a price-to-earnings (P/E) ratio of 40.73, price-to-book of 6.64, price-to-sales of 21.67. Over the past 52 weeks the stock has ranged between $10.93 and $29.75, and currently trades 24.0% below its 52-week high.

On profitability, ZYME generates a return on equity (ROE) of -42.02%, return on capital employed of -34.57%, an operating margin of -19.57%, a net profit margin of -1.26%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides